Publications in collaboration with researchers from Universitat Autònoma de Barcelona (9)

2021

  1. Recommendations for screening, monitoring, prevention, and prophylaxis of infections in adult and pediatric patients receiving CAR T-cell therapy: a position paper

    Infection, Vol. 49, Núm. 2, pp. 215-231

  2. The cost-effectiveness of isavuconazole compared to voriconazole, the standard of care in the treatment of patients with invasive mould diseases, prior to differential pathogen diagnosis in Spain

    Mycoses, Vol. 64, Núm. 1, pp. 66-77

2019

  1. Frequency, characteristics, and outcome of PTLD after allo-SCT: A multicenter study from the Spanish group of blood and marrow transplantation (GETH)

    European Journal of Haematology, Vol. 102, Núm. 6, pp. 465-471

2017

  1. Posicionamiento y actitudes de manejo sobre la profilaxis antifúngica en el paciente hematológico (proyecto PROMIC)

    Revista Espanola de Quimioterapia, Vol. 30, Núm. 3, pp. 213-223

2016

  1. GvHD prophylaxis with tacrolimus plus sirolimus after reduced intensity conditioning allogeneic transplantation: Results of a multicenter study

    Bone Marrow Transplantation

2012

  1. Effect of posaconazole on cyclosporine blood levels and dose adjustment in allogeneic blood and marrow transplant recipients

    Antimicrobial Agents and Chemotherapy, Vol. 56, Núm. 12, pp. 6422-6424

2010

  1. Reduced intensity conditioning HLA identical sibling donor allogeneic stem cell transplantation for patients with follicular lymphoma: Long-term follow-up from two prospective multicenter trials

    Haematologica, Vol. 95, Núm. 7, pp. 1176-1182

2006

  1. Severe Infections after Unrelated Donor Allogeneic Hematopoietic Stem Cell Transplantation in Adults: Comparison of Cord Blood Transplantation with Peripheral Blood and Bone Marrow Transplantation

    Biology of Blood and Marrow Transplantation, Vol. 12, Núm. 7, pp. 734-748

2005

  1. Reduced-intensity conditioning allogeneic blood stem cell transplantation with fludarabine and oral busulfan with or without pharmacokinetically targeted busulfan dosing in patients with myeloid leukemia ineligible for conventional conditioning

    Biology of Blood and Marrow Transplantation, Vol. 11, Núm. 6, pp. 437-447